LEXARIA BIOSCIENCE CORP (LEXX) Stock Fundamental Analysis
USA - NASDAQ:LEXX - US52886N4060 - Common Stock
1.01 USD
+0.03 (+3.06%)
We assign a fundamental rating of 3 out of 10 to LEXX. LEXX was compared to 192 industry peers in the Pharmaceuticals industry. The financial health of LEXX is average, but there are quite some concerns on its profitability. While showing a medium growth rate, LEXX is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year LEXX has reported negative net income.
LEXX had a negative operating cash flow in the past year.
In the past 5 years LEXX always reported negative net income.
In the past 5 years LEXX always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -168.84%, LEXX is doing worse than 85.94% of the companies in the same industry.
Looking at the Return On Equity, with a value of -205.05%, LEXX is doing worse than 70.83% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -168.84% | ||
| ROE | -205.05% | ||
| ROIC | N/A |
ROA(3y)-124.82%
ROA(5y)-108.74%
ROE(3y)-127.55%
ROE(5y)-113.67%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
LEXX has a Gross Margin of 99.56%. This is amongst the best in the industry. LEXX outperforms 98.44% of its industry peers.
In the last couple of years the Gross Margin of LEXX has grown nicely.
LEXX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 99.56% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.01%
GM growth 5Y1.71%
2. Health
2.1 Basic Checks
LEXX does not have a ROIC to compare to the WACC, probably because it is not profitable.
LEXX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, LEXX has more shares outstanding
There is no outstanding debt for LEXX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -6.37, we must say that LEXX is in the distress zone and has some risk of bankruptcy.
LEXX's Altman-Z score of -6.37 is on the low side compared to the rest of the industry. LEXX is outperformed by 63.02% of its industry peers.
LEXX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -6.37 |
ROIC/WACCN/A
WACC7.93%
2.3 Liquidity
LEXX has a Current Ratio of 3.90. This indicates that LEXX is financially healthy and has no problem in meeting its short term obligations.
LEXX has a Current ratio of 3.90. This is in the better half of the industry: LEXX outperforms 64.06% of its industry peers.
LEXX has a Quick Ratio of 3.90. This indicates that LEXX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of LEXX (3.90) is better than 65.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.9 | ||
| Quick Ratio | 3.9 |
3. Growth
3.1 Past
LEXX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -50.00%.
LEXX shows a strong growth in Revenue. In the last year, the Revenue has grown by 61.95%.
LEXX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.11% yearly.
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-61.54%
Revenue 1Y (TTM)61.95%
Revenue growth 3Y-13.6%
Revenue growth 5Y16.11%
Sales Q2Q%107.14%
3.2 Future
LEXX is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -18.48% yearly.
Based on estimates for the next years, LEXX will show a very strong growth in Revenue. The Revenue will grow by 181.98% on average per year.
EPS Next Y-50.04%
EPS Next 2Y-7.38%
EPS Next 3Y-18.48%
EPS Next 5YN/A
Revenue Next Year69.94%
Revenue Next 2Y41.17%
Revenue Next 3Y52.75%
Revenue Next 5Y181.98%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for LEXX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LEXX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
LEXX's earnings are expected to decrease with -18.48% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-7.38%
EPS Next 3Y-18.48%
5. Dividend
5.1 Amount
No dividends for LEXX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:LEXX (10/31/2025, 12:21:11 PM)
1.01
+0.03 (+3.06%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners11.75%
Inst Owner Change-0.12%
Ins Owners7.51%
Ins Owner Change5.43%
Market Cap22.45M
Revenue(TTM)615.90K
Net Income(TTM)-11380000
Analysts82.5
Price Target6.12 (505.94%)
Short Float %4.81%
Short Ratio1.5
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-13.14%
Min EPS beat(2)-31.41%
Max EPS beat(2)5.12%
EPS beat(4)1
Avg EPS beat(4)-20.45%
Min EPS beat(4)-31.41%
Max EPS beat(4)5.12%
EPS beat(8)3
Avg EPS beat(8)-8.37%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)55.65%
Min Revenue beat(2)24.52%
Max Revenue beat(2)86.78%
Revenue beat(4)3
Avg Revenue beat(4)34.67%
Min Revenue beat(4)-52.94%
Max Revenue beat(4)86.78%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)9.09%
EPS NQ rev (1m)5.05%
EPS NQ rev (3m)-9.31%
EPS NY rev (1m)-9.73%
EPS NY rev (3m)-8.56%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)38.6%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 36.45 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 4.05 | ||
| P/tB | 4.46 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.66
EYN/A
EPS(NY)-0.53
Fwd EYN/A
FCF(TTM)-0.44
FCFYN/A
OCF(TTM)-0.44
OCFYN/A
SpS0.03
BVpS0.25
TBVpS0.23
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -168.84% | ||
| ROE | -205.05% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 99.56% | ||
| FCFM | N/A |
ROA(3y)-124.82%
ROA(5y)-108.74%
ROE(3y)-127.55%
ROE(5y)-113.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.01%
GM growth 5Y1.71%
F-Score4
Asset Turnover0.09
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 177.78% | ||
| Cap/Sales | 25.98% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.9 | ||
| Quick Ratio | 3.9 | ||
| Altman-Z | -6.37 |
F-Score4
WACC7.93%
ROIC/WACCN/A
Cap/Depr(3y)176.94%
Cap/Depr(5y)126.17%
Cap/Sales(3y)61.36%
Cap/Sales(5y)40.97%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-61.54%
EPS Next Y-50.04%
EPS Next 2Y-7.38%
EPS Next 3Y-18.48%
EPS Next 5YN/A
Revenue 1Y (TTM)61.95%
Revenue growth 3Y-13.6%
Revenue growth 5Y16.11%
Sales Q2Q%107.14%
Revenue Next Year69.94%
Revenue Next 2Y41.17%
Revenue Next 3Y52.75%
Revenue Next 5Y181.98%
EBIT growth 1Y-137.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-76.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-78.31%
OCF growth 3YN/A
OCF growth 5YN/A
LEXARIA BIOSCIENCE CORP / LEXX FAQ
Can you provide the ChartMill fundamental rating for LEXARIA BIOSCIENCE CORP?
ChartMill assigns a fundamental rating of 3 / 10 to LEXX.
Can you provide the valuation status for LEXARIA BIOSCIENCE CORP?
ChartMill assigns a valuation rating of 0 / 10 to LEXARIA BIOSCIENCE CORP (LEXX). This can be considered as Overvalued.
What is the profitability of LEXX stock?
LEXARIA BIOSCIENCE CORP (LEXX) has a profitability rating of 1 / 10.
What is the expected EPS growth for LEXARIA BIOSCIENCE CORP (LEXX) stock?
The Earnings per Share (EPS) of LEXARIA BIOSCIENCE CORP (LEXX) is expected to decline by -50.04% in the next year.